NewEdge Wealth’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

NewEdge Wealth’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-547,501	Closed	-$3.2M	–	645
2022 Q4	$3.2M	Hold	547,501	–	–	0.14%	141
2022 Q3	$3.67M	Buy	547,501 +210,526	+62%	+$1.28M	0.17%	126
2022 Q2	$1.42M	Hold	336,975	–	–	0.06%	237
2022 Q1	$1.14M	Sell	336,975 -44,351	-12%	-$141K	0.05%	212
2021 Q4	$1.2M	Buy	+381,326	New	+$1.27M	0.05%	219

NewEdge Wealth's CNCE Position: Q1 2023 in Review

NewEdge Wealth sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 547,501 shares — an estimated $3.2M sold.

NewEdge Wealth first reported a position in CNCE in Q4 2021 and held it in 5 quarters. The position peaked at $3.67M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

NewEdge Wealth reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
NewEdge Wealth sold 547,501 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.2M.
NewEdge Wealth first reported a position in Concert Pharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
NewEdge Wealth's Concert Pharmaceuticals, Inc. position peaked at $3.67M in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on NewEdge Wealth's 13F filing for Q1 2023, filed 8 May 2023.